696 results on '"Benoit H. Mulsant"'
Search Results
2. Associations between peripheral inflammation and clinical phenotypes of bipolar depression in a lower-middle income country
- Author
-
Brett D.M. Jones, Urbee Mahmood, John Hodsoll, Imran B. Chaudhry, Ameer B. Khoso, Mohammed O. Husain, Abigail Ortiz, Nusrat Husain, Benoit H. Mulsant, Allan H. Young, and Muhammad I. Husain
- Subjects
Psychiatry and Mental health ,Neurology (clinical) - Abstract
Objective There has been increased interest in repurposing anti-inflammatories for the treatment of bipolar depression. Evidence from high-income countries suggests that these agents may work best for specific depressive symptoms in a subset of patients with biochemical evidence of inflammation but data from lower-middle income countries (LMICs) is scarce. This secondary analysis explored the relationship between pretreatment inflammatory markers and specific depressive symptoms, clinical measures, and demographic variables in participants with bipolar depression in Pakistan. Methods The current study is a cross-sectional secondary analysis of a randomized controlled trial of two anti-inflammatory medications (minocycline and celecoxib) for bipolar depression (n = 266). A series of logistic and linear regression models were completed to assess the relationship between C-reactive protein (CRP) (CRP > or Results The prevalence of low-grade inflammation (CRP > 3 mg/L) in the sample was 70.9%. After adjusting for baseline body mass index, socioeconomic status, age, gender, symptoms related to anhedonia, fatigue, and motor retardation were most associated with low-grade inflammation. Conclusions Bipolar disorder (BD) patients from LMICs may experience higher rates of peripheral inflammation than have been reported in Western populations with BD. Future trials of repurposed anti-inflammatory agents that enrich for participants with these symptom profiles may inform the development of personalized treatment for bipolar depression in LMICs.
- Published
- 2023
3. Recruiting for a Randomized Clinical Trial for Late-Life Depression During COVID-19: Outcomes of Provider Referrals Versus Facebook Self-Referrals
- Author
-
Nicholas J. Ainsworth, Hailey Wright, Ksenya Tereshchenko, Daniel M. Blumberger, Alastair J. Flint, Eric J. Lenze, Athina Perivolaris, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Geriatrics and Gerontology - Published
- 2023
4. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study
- Author
-
Xiaoyu Men, Victoria Marshe, Samar S. Elsheikh, George S. Alexopoulos, Patricia Marino, Barnett S. Meyers, Benoit H. Mulsant, Anthony J. Rothschild, Aristotle N. Voineskos, Ellen M. Whyte, James Lowery Kennedy, Alastair J. Flint, and Daniel J. Müller
- Subjects
Psychiatry and Mental health ,Neuropsychology and Physiological Psychology ,Biological Psychiatry - Abstract
Introduction: Little is known regarding genetic factors associated with treatment outcome of psychotic depression. We explored genomic associations of remission and relapse of psychotic depression treated with pharmacotherapy. Methods: Genomic analyses were performed in 171 men and women aged 18–85 years with an episode of psychotic depression who participated in the Study of the Pharmacotherapy of Psychotic Depression II (STOP-PD II). Participants were treated with open-label sertraline plus olanzapine for up to 12 weeks; those who achieved remission or near-remission and maintained it following 8 weeks of stabilization were eligible to participate in a 36-week randomized controlled trial that compared sertraline plus olanzapine with sertraline plus placebo in preventing relapse. Results: There were no genome-wide significant associations with either remission or relapse. However, at a suggestive threshold, SNP rs1026501 (31 kb from SYNPO2) in the whole sample and rs6844137 (within the intronic region of SYNPO2) in the European ancestry subsample were associated with a decreased likelihood of remission. In polygenic risk analyses, participants who had greater improvement after antidepressant treatments showed a higher likelihood of reaching remission. Those who achieved remission and had a higher polygenic risk for Alzheimer’s disease had a significantly decreased likelihood of relapse. Conclusion: Our analyses provide preliminary insights into the genetic architecture of remission and relapse in a well-characterized group of patients with psychotic depression.
- Published
- 2023
5. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression
- Author
-
Eric J. Lenze, Benoit H. Mulsant, Steven P. Roose, Helen Lavretsky, Charles F. Reynolds, Daniel M. Blumberger, Patrick J. Brown, Pilar Cristancho, Alastair J. Flint, Marie A. Gebara, Torie R. Gettinger, Emily Lenard, J. Philip Miller, Ginger E. Nicol, Hanadi A. Oughli, Vy T. Pham, Bruce L. Rollman, Lei Yang, and Jordan F. Karp
- Subjects
General Medicine - Published
- 2023
6. Major depression, physical health and molecular senescence markers abnormalities
- Author
-
Johanna Seitz-Holland, Benoit H. Mulsant, Charles F. Reynolds III, Daniel M. Blumberger, Jordan F. Karp, Meryl A. Butters, Ana Paula Mendes-Silva, Erica L. Vieira, George Tseng, Eric J. Lenze, and Breno S. Diniz
- Abstract
Previous studies suggested the role of cellular senescence in late-life depression (LLD). However, it is unclear how this finding relates to common features of LLD, such as medical and cognitive problems. We applied factor analyses to an extensive battery of clinical variables in 426 individuals with LLD. Here we tested the relationship between these factors, age and sex, with an index of cellular senescence based on 22 senescence-associated secretory phenotype proteins. We found four factors: ‘depression and anxiety severity’, ‘cognitive functioning’, ‘cardiovascular and cardiometabolic health’ and ‘blood pressure’. A higher senescence-associated secretory phenotype index was associated with poorer ‘cognitive functioning’ and ‘cardiovascular and cardiometabolic health’ but not with ‘depression and anxiety severity’. These findings highlight the role of cellular senescence in poorer physical and cognitive health in LLD. They are consonant with the viewpoint that co-occurring medical burdens and their associated disabilities are part of a phenotype of accelerated ageing in LLD.
- Published
- 2023
7. Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
- Author
-
Hanadi Ajam, Oughli, Marie Anne, Gebara, Adam, Ciarleglio, Helen, Lavretsky, Patrick J, Brown, Alastair J, Flint, Nuri B, Farber, Jordan F, Karp, Benoit H, Mulsant, Charles F, Reynolds, Steven P, Roose, Lei, Yang, Meryl A, Butters, and Eric J, Lenze
- Subjects
Psychiatry and Mental health ,Geriatrics and Gerontology - Abstract
Evidence-based treatment options for late-life treatment-resistant depression (TRD) are limited. Ketamine is a promising treatment for TRD; however, there is a paucity of data on its safety and efficacy in older adults.In this pilot clinical trial, 25 adults aged ≥60 years with TRD received IV ketamine openly twice a week for 4 weeks; partial responders at the end of this acute phase were eligible to receive weekly infusions for 4 more weeks in a continuation phase. Acceptability, tolerability, and safety, including adverse and serious adverse events (AEs and SAEs), blood pressure changes, dissociation, craving, in addition to rates of depression response and remission were evaluated. The NIH Toolbox Cognitive Battery was used to assess specific measures of executive function (EF) and overall fluid cognition.Completion rates were 88% for the acute phase and 100% for the continuation phase. No AEs resulted in participant discontinuation, and there were no SAEs. Treatment-emergent elevation of blood pressure, dissociation, and craving were transient and did not result in any participant discontinuation. Depressive symptoms improved significantly and 48% of participants responded. During the acute phase, the EF measures and the fluid cognition composite score improved (Cohen's d = 0.61), and these improvements were sustained in the continuation phase.This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD. These promising findings need to be confirmed and extended in a larger randomized controlled trial.
- Published
- 2023
8. Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial
- Author
-
Alastair J. Flint, Kathleen S. Bingham, George S. Alexopoulos, Patricia Marino, Benoit H. Mulsant, Nicholas H. Neufeld, Anthony J. Rothschild, Aristotle N. Voineskos, Ellen M. Whyte, and Barnett S. Meyers
- Subjects
Psychiatry and Mental health ,Biological Psychiatry - Abstract
Psychotic depression has a high rate of relapse. The study aims were to identify a prediction model of risk of relapse of psychotic depression and examine whether predictors moderated the effect of treatment on relapse. One hundred and twenty-six men and women aged 18-85 years, who experienced sustained remission or near-remission of psychotic depression with sertraline plus olanzapine, participated in a 36-week randomized controlled trial that compared sertraline plus olanzapine with sertraline plus placebo in preventing relapse (NCT01427608). Cox regression analyses were performed to identify significant predictors of relapse and to model the combined role of significant predictors. Concordance statistic was calculated to determine the accuracy of the best fit multivariable models in predicting relapse. Finally, interaction terms were tested for each significant predictor to examine whether they moderated the effect of treatment on risk of relapse. Lifetime number of depressive episodes, severity of residual depressive symptoms at the time of randomization, and psychomotor disturbance both at acute enrollment when participants were depressed and at the time of randomization predicted risk of relapse. Multivariable models had 69-70% accuracy in predicting relapse. Psychomotor disturbance was associated with increased risk of relapse in the sertraline plus olanzapine group compared with sertraline plus placebo, whereas the other predictors did not moderate the effect of treatment on relapse. Future research is needed to determine whether a combination of clinical and biological variables can further increase the accuracy of prediction of relapse of psychotic depression.
- Published
- 2023
9. Sex-specific associations between lifetime diagnosis of bipolar disorder and cardiovascular disease: A cross-sectional analysis of 257,673 participants from the UK Biobank
- Author
-
Abigail Ortiz, Marcos Sanches, Mohamed Abdelhack, Tyler R. Schwaiger, Michael Wainberg, Shreejoy J. Tripathy, Daniel Felsky, Benoit H. Mulsant, and Jess G. Fiedorowicz
- Subjects
Male ,Heart Failure ,Bipolar Disorder ,Coronary Artery Disease ,United Kingdom ,Psychiatry and Mental health ,Clinical Psychology ,Cross-Sectional Studies ,Cardiovascular Diseases ,Risk Factors ,Humans ,Female ,Essential Hypertension ,Biomarkers ,Biological Specimen Banks - Abstract
Sex is seldom considered as a potential moderator of the impact of bipolar disorder (BD) on cardiovascular disease (CVD) risk. We aimed to characterize the sex-specific association of CVD and BD using data from the UK Biobank.In a cross-sectional analysis, we compared the odds ratio between women and men with BD for seven CVD diagnoses (coronary artery disease, myocardial infarction, angina, atrial fibrillation, heart failure, stroke, and essential hypertension) and four cardiovascular biomarkers (arterial stiffness index, low-density lipoprotein, C-reactive protein, and HbA1c) in 293 participants with BD and 257,380 psychiatrically healthy controls in the UK Biobank.After adjusting for age, we found a two- to three-fold stronger association among women than among men between BD and rates of coronary artery disease, heart failure, and essential hypertension, with a significant sex-by-diagnosis interactions. The association remained significant after controlling for self-reported race, education, income, and smoking status. After controlling for potential confounders, there was no significant association between sex and any cardiovascular biomarkers.These analyses could not disentangle effects of BD from its treatment.Our results underscore the importance of incorporating sex and mental illness in risk estimation tools for CVD, and improving screening for, and timely treatment of, CVD in those with BD. Future research is needed to better understand the contributors and mechanisms of sex differences related to CVD risk in BD.
- Published
- 2022
10. A Qualitative Analysis of Suicide Notes to Understand Suicidality in Older Adults
- Author
-
Ari B, Cuperfain, Zainab, Furqan, Mark, Sinyor, Benoit H, Mulsant, Kenneth, Shulman, Paul, Kurdyak, and Juveria, Zaheer
- Subjects
Aged, 80 and over ,Ontario ,Suicide ,Psychiatry and Mental health ,Risk Factors ,Mental Disorders ,Loneliness ,Humans ,Geriatrics and Gerontology ,Aged ,Suicidal Ideation - Abstract
Suicide is a complex multifactorial process influenced by a variety of biological, psychological, and social stressors. Many older adults face a characteristic set of challenges that predispose them to suicidal ideation, suicide-related behavior, and death by suicide. This study explored the subjective experience of suicidality through the analysis of suicide notes from older adults.Qualitative study analyzing written suicide notes.Written notes for suicide deaths in Toronto, Canada, between 2003 and 2009 were obtained from the Office of the Chief Coroner for Ontario.The analysis comprised 29 suicide notes (mean words per note: 221; range: 6-1095) written by individuals 65 years and older (mean ± SD age: 76.2 ± 8.3).We employed a constructivist grounded theory framework for the analysis, conducted through line-by-line open coding, axial coding, and theorizing of data to establish themes.Suicide notes elucidated the writers' conception of suicide and their emotional responses to stressors. Expressed narratives contributing to suicide centered on burdensomeness or guilt, experiences of mental illness, loneliness or isolation, and poor physical health or disability. Terms related to pain, poor sleep, apology, and inability to go on were recurrent.Suicide notes enrich our understanding of the thoughts and emotions of those at highest risk of suicide, and they inform potential interventions for reducing suicide risk in older adults.
- Published
- 2022
11. Bipolar I and bipolar <scp>II</scp> subtypes in older age: Results from the Global Aging and Geriatric Experiments in Bipolar Disorder ( <scp>GAGE‐BD</scp> ) project
- Author
-
Alexandra J. M. Beunders, Federica Klaus, Almar A. L. Kok, Sigfried N. T. M. Schouws, Ralph W. Kupka, Hilary P. Blumberg, Farren Briggs, Lisa T. Eyler, Brent P. Forester, Orestes V. Forlenza, Ariel Gildengers, Esther Jimenez, Benoit H. Mulsant, Regan E. Patrick, Soham Rej, Martha Sajatovic, Kaylee Sarna, Ashley Sutherland, Joy Yala, Eduard Vieta, Luca M. Villa, Nicole C. M. Korten, Annemieke Dols, APH - Mental Health, Psychiatry, APH - Aging & Later Life, Neurology, and Amsterdam Neuroscience - Neurodegeneration
- Subjects
cognition ,Aging ,impairment ,Bipolar Disorder ,Clinical Sciences ,comorbidities ,elderly ,functioning ,Clinical Research ,Humans ,Cognitive Dysfunction ,Aetiology ,Biological Psychiatry ,Aged ,Psychiatry ,geriatrics ,Depression ,Neurosciences ,Serious Mental Illness ,older-age bipolar disorder ,Brain Disorders ,Psychiatry and Mental health ,Cross-Sectional Studies ,Mental Health ,diagnostic subtypes ,2.4 Surveillance and distribution - Abstract
ObjectivesThe distinction between bipolar I disorder (BD-I) and bipolar II disorder (BD-II) has been a topic of long-lasting debate. This study examined differences between BD-I and BD-II in a large, global sample of OABD, focusing on general functioning, cognition and somatic burden as these domains are often affected in OABD.MethodsCross-sectional analyses were conducted with data from the Global Aging and Geriatric Experiments in Bipolar Disorder (GAGE-BD) database. The sample included 963 participants aged ≥50 years (714 BD-I, 249 BD-II). Sociodemographic and clinical factors were compared between BD subtypes including adjustment for study cohort. Multivariable analyses were conducted with generalized linear mixed models (GLMMs) and estimated associations between BD subtype and (1) general functioning (GAF), (2) cognitive performance (g-score) and (3) somatic burden, with study cohort as random intercept.ResultsAfter adjustment for study cohort, BD-II patients more often had a late onset ≥50 years (p=0.008) and more current severe depression (p=0.041). BD-I patients were more likely to have a history of psychiatric hospitalization (p
- Published
- 2022
12. Symptom Severity Mixity in Older-Age Bipolar Disorder: Analyses From the Global Aging and Geriatric Experiments in Bipolar Disorder Database (GAGE-BD)
- Author
-
Lisa T. Eyler, Farren B.S. Briggs, Annemiek Dols, Soham Rej, Osvaldo P. Almeida, Alexandra J.M. Beunders, Hilary P. Blumberg, Brent P. Forester, Regan E. Patrick, Orestes V. Forlenza, Ariel Gildengers, Esther Jimenez, Eduard Vieta, Benoit H. Mulsant, Sigfried Schouws, Nadine P.G. Paans, Sergio Strejilevich, Ashley Sutherland, Shangying Tsai, Martha Sajatovic, Neurology, Psychiatry, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, and APH - Mental Health
- Subjects
Cohort Studies ,Aging ,Mania ,Psychiatry and Mental health ,Bipolar Disorder ,Cross-Sectional Studies ,Humans ,Geriatrics and Gerontology ,Aged - Abstract
Objective: Some individuals with bipolar disorder (BD) experience manic and depressive symptoms concurrently, but data are limited on symptom mixity in older age bipolar disorder (OABD). Using the Global Aging & Geriatric Experiments in Bipolar Disorder Database, we characterized mixity in OABD and associations with everyday function. Methods: The sample (n = 805), from 12 international studies, included cases with both mania and depression severity ratings at a single timepoint. Four mixity groups were created: asymptomatic (A), mixed (Mix), depressed only (Dep), and manic only (Man). Generalized linear mixed models used mixity group as the predictor variable; cohort was included as a random intercept. Everyday function was assessed with the Global Assessment of Functioning score. Results: Group proportions were Mix (69.6%; n = 560), followed by Dep (18.4%; n = 148), then A (7.8%; n = 63), then Man (4.2%; n= 34); levels of depression and mania were similar in Mix compared to Dep and Man, respectively. Everyday function was lowest in Mix, highest in A, and intermediate in Man and Dep. Within Mix, severity of depression was the main driver of worse functioning. Groups differed in years of education, with A higher than all others, but did not differ by age, gender, employment status, BD subtype, or age of onset. Conclusions: Mixed features predominate in a cross-sectional, global OABD sample and are associated with worse everyday function. Among those with mixed symptoms, functional status relates strongly to current depression severity. Future studies should include cognitive and other biological variables as well as longitudinal designs to allow for evaluation of causal effects.
- Published
- 2022
13. Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial
- Author
-
Helene M, Altmann, Joseph, Kazan, Marie Anne, Gebara, Daniel M, Blumberger, Jordan F, Karp, Eric J, Lenze, Benoit H, Mulsant, Charles F, Reynolds, and Sarah T, Stahl
- Subjects
Depressive Disorder, Major ,Psychiatry and Mental health ,Depression ,Venlafaxine Hydrochloride ,Humans ,Geriatrics and Gerontology ,Antidepressive Agents ,Aged ,Medication Adherence - Abstract
Nonadherence to antidepressants interferes with optimal treatment of late-life depression. This analysis examines clinical and treatment factors predicting medication nonadherence in difficult-to-treat late-life depression.Secondary analysis of data from a clinical trial of antidepressant pharmacotherapy for Major Depressive Disorder in 468 adults aged 60+ years. All participants received venlafaxine XR for 12 weeks. Nonremitters were randomized to augmentation with either aripiprazole or placebo for 12 additional weeks. Medication adherence was assessed 14 times over 24 weeks. The analyses examined sociodemographic, clinical, and treatment factors that may predict antidepressant nonadherence during early (weeks 1-6), late (weeks 7-12), and augmentation (weeks 13--24) treatment.Poor cognitive function and early response were predictive of early nonadherence. Poor cognitive function and prior nonadherence were predictive of late nonadherence. Living alone was associated with nonadherence both late and during augmentation treatment.Future studies should consider the role of early response and cognitive function to improve antidepressant adherence, particularly among older adults who live alone.
- Published
- 2022
14. Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study
- Author
-
Helena K. Kim, Gwyneth Zai, Daniel J. Müller, Muhammad I. Husain, Raymond W. Lam, Benicio N. Frey, Claudio N. Soares, Sagar V. Parikh, Roumen Milev, Jane A. Foster, Gustavo Turecki, Faranak Farzan, Benoit H. Mulsant, Sidney H. Kennedy, Shreejoy J. Tripathy, and Stefan Kloiber
- Subjects
Canada ,Depressive Disorder, Major ,Aripiprazole ,General Medicine ,Psychiatry and Mental health ,Treatment Outcome ,Escitalopram ,Double-Blind Method ,Humans ,Pharmacology (medical) ,RNA, Messenger ,Biomarkers ,Endocannabinoids ,Genome-Wide Association Study - Abstract
Introduction An increasing number of studies are examining the link between the endocannabinoidome and major depressive disorder (MDD). We conducted an exploratory analysis of this system to identify potential markers of treatment outcomes. Methods The dataset of the Canadian Biomarker Integration Network in Depression-1 study, consisting of 180 patients with MDD treated for eight weeks with escitalopram followed by eight weeks with escitalopram alone or augmented with aripiprazole was analyzed. Association between response Montgomery-Asberg Depression Rating Scale (MADRS; score reduction≥50%) or remission (MADRS score≤10) at weeks 8 and 16 and single nucleotide polymorphisms (SNPs), methylation, and mRNA levels of 33 endocannabinoid markers were examined. A standard genome-wide association studies protocol was used for identifying SNPs, and logistic regression was used to assess methylation and mRNA levels. Results Lower methylation of CpG islands of the diacylglycerol lipase alpha gene (DAGLA) was associated with non-remission at week 16 (DAGLA; OR=0.337, p Discussion Methylation of DAGLA is a promising candidate as a marker of treatment outcomes for MDD and needs to be explored further.
- Published
- 2022
15. Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features
- Author
-
Nicholas H. Neufeld, Lindsay D. Oliver, Benoit H. Mulsant, George S. Alexopoulos, Matthew J. Hoptman, Hideaki Tani, Patricia Marino, Barnett S. Meyers, Anthony J. Rothschild, Ellen M. Whyte, Kathleen S. Bingham, Alastair J. Flint, and Aristotle N. Voineskos
- Subjects
Cellular and Molecular Neuroscience ,Psychiatry and Mental health ,Molecular Biology - Published
- 2023
16. Predictors of adherence to electronic self-monitoring in patients with bipolar disorder: a contactless study using Growth Mixture Models
- Author
-
Abigail Ortiz, Yunkyung Park, Christina Gonzalez-Torres, Martin Alda, Daniel M. Blumberger, Rachael Burnett, M. Ishrat Husain, Marcos Sanches, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Biological Psychiatry - Abstract
Background Several studies have reported on the feasibility of electronic (e-)monitoring using computers or smartphones in patients with mental disorders, including bipolar disorder (BD). While studies on e-monitoring have examined the role of demographic factors, such as age, gender, or socioeconomic status and use of health apps, to our knowledge, no study has examined clinical characteristics that might impact adherence with e-monitoring in patients with BD. We analyzed adherence to e-monitoring in patients with BD who participated in an ongoing e-monitoring study and evaluated whether demographic and clinical factors would predict adherence. Methods Eighty-seven participants with BD in different phases of the illness were included. Patterns of adherence for wearable use, daily and weekly self-rating scales over 15 months were analyzed to identify adherence trajectories using growth mixture models (GMM). Multinomial logistic regression models were fitted to compute the effects of predictors on GMM classes. Results Overall adherence rates were 79.5% for the wearable; 78.5% for weekly self-ratings; and 74.6% for daily self-ratings. GMM identified three latent class subgroups: participants with (i) perfect; (ii) good; and (iii) poor adherence. On average, 34.4% of participants showed “perfect” adherence; 37.1% showed “good” adherence; and 28.2% showed poor adherence to all three measures. Women, participants with a history of suicide attempt, and those with a history of inpatient admission were more likely to belong to the group with perfect adherence. Conclusions Participants with higher illness burden (e.g., history of admission to hospital, history of suicide attempts) have higher adherence rates to e-monitoring. They might see e-monitoring as a tool for better documenting symptom change and better managing their illness, thus motivating their engagement.
- Published
- 2023
17. Manipulating facial musculature with functional electrical stimulation as an intervention for major depressive disorder: a focused search of literature for a proposal
- Author
-
Ilya Demchenko, Naaz Desai, Stephanie N. Iwasa, Fatemeh Gholamali Nezhad, José Zariffa, Sidney H. Kennedy, Nicholas O. Rule, Jeffrey F. Cohn, Milos R. Popovic, Benoit H. Mulsant, and Venkat Bhat
- Subjects
Rehabilitation ,Health Informatics - Abstract
Background Major Depressive Disorder (MDD) is associated with interoceptive deficits expressed throughout the body, particularly the facial musculature. According to the facial feedback hypothesis, afferent feedback from the facial muscles suffices to alter the emotional experience. Thus, manipulating the facial muscles could provide a new “mind-body” intervention for MDD. This article provides a conceptual overview of functional electrical stimulation (FES), a novel neuromodulation-based treatment modality that can be potentially used in the treatment of disorders of disrupted brain connectivity, such as MDD. Methods A focused literature search was performed for clinical studies of FES as a modulatory treatment for mood symptoms. The literature is reviewed in a narrative format, integrating theories of emotion, facial expression, and MDD. Results A rich body of literature on FES supports the notion that peripheral muscle manipulation in patients with stroke or spinal cord injury may enhance central neuroplasticity, restoring lost sensorimotor function. These neuroplastic effects suggest that FES may be a promising innovative intervention for psychiatric disorders of disrupted brain connectivity, such as MDD. Recent pilot data on repetitive FES applied to the facial muscles in healthy participants and patients with MDD show early promise, suggesting that FES may attenuate the negative interoceptive bias associated with MDD by enhancing positive facial feedback. Neurobiologically, the amygdala and nodes of the emotion-to-motor transformation loop may serve as potential neural targets for facial FES in MDD, as they integrate proprioceptive and interoceptive inputs from muscles of facial expression and fine-tune their motor output in line with socio-emotional context. Conclusions Manipulating facial muscles may represent a mechanistically novel treatment strategy for MDD and other disorders of disrupted brain connectivity that is worthy of investigation in phase II/III trials.
- Published
- 2023
18. Support to caregivers who have received genetic information about neurodevelopmental and psychiatric vulnerability in their young children: A narrative review
- Author
-
Polina Perlman, Jacob Vorstman, Ny Hoang, Jane Summers, Danielle Baribeau, Jessie Cunningham, and Benoit H. Mulsant
- Subjects
Genetics ,Genetics (clinical) - Published
- 2023
19. Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric psychiatry unit
- Author
-
Sanjeev Kumar, Amruta Shanbhag, Amer M. Burhan, Sarah Colman, Philip Gerretsen, Ariel Graff-Guerrero, Donna Kim, Clement Ma, Benoit H. Mulsant, Bruce G. Pollock, Vincent L. Woo, Simon J.C. Davies, and Tarek K. Rajji
- Subjects
Inpatients ,Psychotropic Drugs ,Delivery of Health Care, Integrated ,Geriatric Psychiatry ,Psychiatry and Mental health ,Clinical Psychology ,Humans ,Dementia ,Prospective Studies ,Geriatrics and Gerontology ,Gerontology ,Psychomotor Agitation ,Aged ,Retrospective Studies - Abstract
Objectives:This study examined the effectiveness of an integrated care pathway (ICP), including a medication algorithm, to treat agitation associated with dementia.Design:Analyses of data (both prospective and retrospective) collected during routine clinical care.Setting:Geriatric Psychiatry Inpatient Unit.Participants:Patients with agitation associated with dementia (n = 28) who were treated as part of the implementation of the ICP and those who received treatment-as-usual (TAU) (n = 28) on the same inpatient unit before the implementation of the ICP. Two control groups of patients without dementia treated on the same unit contemporaneously to the TAU (n = 17) and ICP groups (n = 36) were included to account for any secular trends.Intervention:ICP.Measurements:Cohen Mansfield Agitation Inventory (CMAI), Neuropsychiatric Inventory Questionnaire (NPIQ), and assessment of motor symptoms were completed during the ICP implementation. Chart review was used to obtain length of inpatient stay and rates of psychotropic polypharmacy.Results:Patients in the ICP group experienced a reduction in their scores on the CMAI and NPIQ and no changes in motor symptoms. Compared to the TAU group, the ICP group had a higher chance of an earlier discharge from hospital, a lower rate of psychotropic polypharmacy, and a lower chance of having a fall during hospital stay. In contrast, these outcomes did not differ between the two control groups.Conclusions:These preliminary results suggest that an ICP can be used effectively to treat agitation associated with dementia in inpatients. A larger randomized study is needed to confirm these results.
- Published
- 2022
20. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta‐analysis
- Author
-
Robert A. McCutcheon, Toby Pillinger, Orestis Efthimiou, Marta Maslej, Benoit H. Mulsant, Allan H. Young, Andrea Cipriani, and Oliver D. Howes
- Subjects
Psychiatry and Mental health ,Research Reports ,Pshychiatric Mental Health ,610 Medicine & health ,360 Social problems & social services - Abstract
It is common experience for practising psychiatrists that individuals with schizophrenia vary markedly in their symptomatic response to antipsychotic medication. What is not clear, however, is whether this variation reflects variability of medication-specific effects (also called "treatment effect heterogeneity"), as opposed to variability of non-specific effects such as natural symptom fluctuation or placebo response. Previous meta-analyses found no evidence of treatment effect heterogeneity, suggesting that a "one size fits all" approach may be appropriate and that efforts at developing personalized treatment strategies for schizophrenia are unlikely to succeed. Recent advances indicate, however, that earlier approaches may have been unable to accurately quantify treatment effect heterogeneity due to their neglect of a key parameter: the correlation between placebo response and medication-specific effects. In the present paper, we address this shortcoming by using individual patient data and study-level data to estimate that correlation and quantitatively characterize antipsychotic treatment effect heterogeneity in schizophrenia. Individual patient data (on 384 individuals who were administered antipsychotic treatment and 88 who received placebo) were obtained from the Yale University Open Data Access (YODA) database. Study-level data were obtained from a meta-analysis of 66 clinical trials including 17,202 patients. Both individual patient and study-level analyses yielded a negative correlation between placebo response and treatment effect for the total score on the Positive and Negative Syndrome Scale (PANSS) (ρ=-0.32, p=0.002 and ρ=-0.39, p
- Published
- 2022
21. Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?
- Author
-
M. Ishrat Husain, Madeha Umer, and Benoit H. Mulsant
- Subjects
Mental Disorders ,Hallucinogens ,Humans ,Pharmacology (medical) ,General Medicine ,Risk Assessment - Published
- 2022
22. Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
- Author
-
Kevin J. Black, Jennifer I. Lissemore, Zafiris J. Daskalakis, Tarek K. Rajji, Jonathan McConathy, Jordan F. Karp, Songye Li, Zhude Tu, Hyewon Helen Lee, Daphne Voineskos, Benoit H. Mulsant, Eric J. Lenze, M Deanna, Daniel M. Blumberger, Yi Su, Pilar Cristancho, Sarah A. Eisenstein, Yiyun Huang, Charles F. Reynolds, and Stewart J. Anderson
- Subjects
business.industry ,medicine.medical_treatment ,General Medicine ,medicine.disease ,Placebo ,law.invention ,Clinical trial ,Transcranial magnetic stimulation ,Randomized controlled trial ,Tolerability ,law ,Anesthesia ,Brain positron emission tomography ,Medicine ,business ,Treatment-resistant depression ,Buprenorphine ,medicine.drug - Abstract
Background The experimental therapeutics approach that combines a placebo-controlled clinical trial with translational neuroscience methods can provide a better understanding of both the clinical and physiological effects of pharmacotherapy. We aimed to test the efficacy and tolerability of low-dose augmentation with buprenorphine (BPN) for treatment resistant depression, combined with multi-modal assessment of target engagement. Methods In this multi-site, randomized clinical trial, 85 participants ≥ age 50 with a major depressive episode that had not responded to venlafaxine XR were randomized to augmentation with BPN or placebo for 8 weeks. The primary outcome measure was the Montgomery-Asberg Depression Rating Scale (MADRS). In addition, three linked experiments were conducted to test target engagement: 1) functional magnetic resonance imaging (fMRI) using the Monetary Incentive Delay Task; 2) brain positron emission tomography (PET) of healthy participants using a novel kappa opioid receptor (κ-OR) antagonist tracer [11C]LY2795050; 3) transcranial magnetic stimulation (TMS) measure of cortical transmission after daily BPN administration. Results The mean ± SD dosage of BPN was 0.59±0.33 mg/day. There were no significant differences between the BPN and placebo groups in MADRS changes over time or adverse effects. BPN administration had minimal effects on fMRI bold responses in regions involved in reward anticipation and response, no significant displacement of κ-OR radioligand in PET imaging, and no significant changes in TMS measures of inhibitory and excitatory cortical transmission. Conclusions Our findings suggest a lack of clinical effect of low-dose BPN augmentation and lack of target engagement with this dosage and physiological probes.
- Published
- 2022
23. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
- Author
-
Muhammad Ishrat Husain, Nicole Ledwos, Elise Fellows, Jenna Baer, Joshua D. Rosenblat, Daniel M. Blumberger, Benoit H. Mulsant, and David J. Castle
- Subjects
Psychiatry and Mental health - Abstract
IntroductionCurrent treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological underpinnings of the mechanism of antidepressant action of these drugs.MethodsA narrative review was conducted using PubMed to identify published articles evaluating the antidepressant mechanism of action of serotonergic psychedelics.ResultsSerotonergic psychedelics have serotonin (5HT)2A agonist or partial agonist effects. Their rapid antidepressant effects may be mediated—in part—by their potent 5HT2A agonism, leading to rapid receptor downregulation. In addition, these psychedelics impact brain derived neurotrophic factor and immunomodulatory responses, both of which may play a role in their antidepressant effect. Several neuroimaging and neurophysiology studies evaluating mechanistic change from a network perspective can help us to further understand their mechanism of action. Some, but not all, data suggest that psychedelics may exert their effects, in part, by disrupting the activity of the default mode network, which is involved in both introspection and self-referential thinking and is over-active in MDD.ConclusionThe mechanisms of action underlying the antidepressant effect of serotonergic psychedelics remains an active area of research. Several competing theories are being evaluated and more research is needed to determine which ones are supported by the most robust evidence.
- Published
- 2023
24. A systematic review on the effectiveness of dialectical behavior therapy for improving mood symptoms in bipolar disorders
- Author
-
Brett D. M. Jones, Madeha Umer, Mary E. Kittur, Ofer Finkelstein, Siqi Xue, Mikaela K. Dimick, Abigail Ortiz, Benjamin I. Goldstein, Benoit H. Mulsant, and Muhammad I. Husain
- Subjects
Psychiatry and Mental health ,Biological Psychiatry - Abstract
Background Evidence-based psychotherapies available to treat patients with bipolar disorders (BD) are limited. Dialectical behavior therapy (DBT) may target several common symptoms of BD. We conducted a systematic review on the efficacy of DBT for mood symptoms in patients with BD. The systematic search used key words related to DBT and BD in Medline, Embase, PsycInfo, CINAHL, and Cochrane Library databases from 1980 to April 1st, 2022. We included studies that enrolled patients with a BD I or II diagnosis (DSM or ICD), age 12 and older who received a DBT-based intervention. Studies reviewed were clinical trials including observational studies that reported at least one outcome related to BD mood symptoms or severity. We did not exclude based upon psychiatric or physical co-morbidity. Results We screened 848 abstracts and reviewed 28 full texts; 10 publications with 11 studies met our pre-determined eligibility criteria. All but one were feasibility pilot studies and most included participants in all mood states except for mania. The studies provided preliminary evidence suggesting these interventions may be effective for improving several core symptoms of BD. Overall, all the studies consistently supported that DBT-based interventions are feasible and acceptable for patients with BD. Conclusion DBT may be an effective treatment for BD; however, the confidence in this conclusion is limited by the small sample sizes, heterogeneity, and high risk of bias in all published trials. Larger well-designed RCTs are now required to establish the effectiveness of DBT in BD.
- Published
- 2023
25. Association between lean muscle mass and treatment-resistant late-life depression in the IRL-GRey randomized controlled trial
- Author
-
Nicholas J. Ainsworth, Ram Brender, Neta Gotlieb, Haoyu Zhao, Daniel M. Blumberger, Jordan F. Karp, Eric J. Lenze, Ginger E. Nicol, Charles F. Reynolds, Wei Wang, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,Geriatrics and Gerontology ,Gerontology - Abstract
Objective: To investigate the relationship between lean muscle mass and treatment response in treatment-resistant late-life depression (TR-LLD). We hypothesized that lower lean muscle mass would be associated with older age, higher physical comorbidities, higher depressive symptom severity, and poorer treatment response. Design: Secondary analysis of a randomized, placebo-controlled trial. Setting: Three academic hospitals in the United States and Canada. Participants: Adults aged 60+ years with major depressive disorder who did not remit following open treatment with venlafaxine extended-release (XR) (n = 178). Measurements: We estimated lean muscle mass using dual-energy X-ray absorptiometry (DEXA) scans prior to and following randomized treatment with aripiprazole or placebo added to venlafaxine XR. Multivariate regressions estimated influence of demographic and clinical factors on baseline lean muscle mass, and whether baseline lean muscle mass was associated with treatment response, adjusted for treatment arm. Results: Low lean muscle mass was present in 22 (12.4%) participants. Older age and female sex, but not depressive symptom severity, were independently associated with lower lean muscle mass at baseline. Marital status, baseline depressive symptom severity, and treatment group were associated with improvement of depressive symptoms in the randomized treatment phase. Baseline lean muscle mass was not associated with improvement, regardless of treatment group. Conclusion: As expected, older age and female sex were associated with lower lean muscle mass in TR-LLD. However, contrary to prior results in LLD, lean muscle mass was not associated with depression severity or outcome. This suggests that aripiprazole augmentation may be useful for TR-LLD, even in the presence of anomalous body composition. clinicaltrials.gov Identifier: NCT00892047.
- Published
- 2023
26. The Rationale and Design of Behavioral Interventions for Management of Agitation in Dementia in a Multi-Site Clinical Trial
- Author
-
Shadi, Zarei, Sarah, Colman, Aviva, Rostas, Amer M, Burhan, Li, Chu, Simon Jc, Davies, Peter, Derkach, Sarah, Elmi, Maria, Hussain, Philip, Gerretsen, Ariel, Graff-Guerrero, Zahinoor, Ismail, Donna, Kim, Linda, Krisman, Rola, Moghabghab, Benoit H, Mulsant, Vasavan, Nair, Bruce G, Pollock, Soham, Rej, Jyll, Simmons, Lisa, Van Bussel, Tarek K, Rajji, and Sanjeev, Kumar
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,Caregivers ,General Neuroscience ,Quality of Life ,Humans ,Dementia ,General Medicine ,Anxiety ,Geriatrics and Gerontology ,Psychomotor Agitation - Abstract
Background: Agitation and aggression are common in patients with Alzheimer’s disease and related dementias and pose a significant burden on patients, caregivers, and the healthcare systems. Guidelines recommend personalized behavioral interventions as the first-line treatment; however, these interventions are often underutilized. The Standardizing Care for Neuropsychiatric Symptoms and Quality of Life in Dementia (StaN) study (ClinicalTrials.gov Identifier # NCT0367220) is a multisite randomized controlled trial comparing an Integrated Care Pathway, that includes a sequential pharmacological algorithm and structured behavioral interventions, with treatment-as-usual to treat agitation in dementia in long-term care and inpatient settings. Objective: To describe the rationale and design of structured behavioral interventions in the StaN study. Methods: Structured behavioral interventions are designed and implemented based on the following considerations: 1) personalization, 2) evidence base, 3) dose and duration, 4) measurement-based care, and 5) environmental factors and feasibility. Results: The process to design behavioral interventions for each individual starts with a comprehensive assessment, followed by personalized, evidence-based interventions delivered in a standardized manner with ongoing monitoring of global clinical status. Measurement-based care is used to tailor the interventions and integrate them with pharmacotherapy. Conclusion: Individualized behavioral interventions in patients with dementia may be challenging to design and implement. Here we describe a process to design and implement individualized and structured behavioral interventions in the context of a multisite trial in long-term care and inpatient settings. This process can inform the design of behavioral interventions in future trials and in clinical settings for the treatment of agitation in dementia.
- Published
- 2022
27. Transcranial Magnetic Stimulation Indices of Cortical Excitability Enhance the Prediction of Response to Pharmacotherapy in Late-Life Depression
- Author
-
Zafiris J. Daskalakis, Tarek K. Rajji, Jonathan Downar, Reza Zomorrodi, Jordan F. Karp, Benoit H. Mulsant, Charles F. Reynolds, Eric J. Lenze, Meryl A. Butters, Daniel M. Blumberger, Anthony J. Bonner, Jennifer I. Lissemore, and Robert Chen
- Subjects
medicine.medical_specialty ,Treatment response ,Cognitive Neuroscience ,medicine.medical_treatment ,Venlafaxine ,Article ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Pharmacotherapy ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Biological Psychiatry ,Depression (differential diagnoses) ,Aged ,030304 developmental biology ,0303 health sciences ,Depression ,business.industry ,Venlafaxine Hydrochloride ,Late life depression ,Neurophysiology ,Transcranial Magnetic Stimulation ,3. Good health ,Transcranial magnetic stimulation ,Inhibition, Psychological ,Brain stimulation ,Cortical Excitability ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
BACKGROUND. Older adults with late-life depression (LLD) often experience incomplete or lack of response to first-line pharmacotherapy. The treatment of LLD could be improved using objective biological measures to predict response. Transcranial magnetic stimulation (TMS) can be used to measure cortical excitability, inhibition, and plasticity, which have been implicated in LLD pathophysiology, and associated with brain stimulation treatment outcomes in younger adults with depression. TMS measures have not yet been investigated as predictors of treatment outcomes in LLD, or pharmacotherapy outcomes in adults of any age with depression. METHODS. We assessed whether pre-treatment single-pulse and paired-pulse TMS measures, combined with clinical and demographic measures, predict venlafaxine treatment response in 76 outpatients with LLD. We compared the predictive performance of machine learning models including or excluding TMS predictors. RESULTS. Two single-pulse TMS measures predicted venlafaxine response: cortical excitability (neuronal membrane excitability), and the variability of cortical excitability (dynamic fluctuations in excitability levels). In cross-validation, models using a combination of these TMS predictors, clinical markers of treatment resistance, and age, classified patients with 73±11% balanced accuracy (average correct classification rate of responders and non-responders; permutation testing, p
- Published
- 2022
28. Technology‐enabled collaborative care for youth with early psychosis: Results of a feasibility study to improve physical health behaviours
- Author
-
Osnat Melamed, Aristotle Voineskos, Lenka Vojtila, Iqra Ashfaq, Scott Veldhuizen, Rosa Dragonetti, Rebecca Carriere, Laura LaChance, Sara Ahola Kohut, Trisha Tulloch, Sri Mahavir Argarwal, Margaret Hahn, Benoit H. Mulsant, and Peter Selby
- Subjects
Adult ,Ontario ,Technology ,Young Adult ,Psychiatry and Mental health ,Adolescent ,Psychotic Disorders ,Health Behavior ,Feasibility Studies ,Humans ,Pshychiatric Mental Health ,Biological Psychiatry - Abstract
Psychotic disorders are associated with excess morbidity and premature mortality. Contributing factors include tobacco smoking, low physical activity, and poor nutrition. This study tested a Technology-Enabled Collaborative Care model to improve health behaviours among youth with early psychosis.A feasibility study among youth (ages 16-29) with early psychosis in Ontario, Canada. Participants were randomized to either a health coach supervised by a virtual care team (high intensity, n = 29), or self-directed learning (low intensity, n = 23) for 12 weeks. The primary outcome was participant engagement, defined as self-perceived benefit of changing health behaviours. Secondary outcomes were measures of health behaviours and programme-use metrics.Engagement was higher for high intensity participants for physical activity (adjusted group difference in change at 24 weeks = 3.4, CI95% = 1.9-4.9, p .001) and nutrition (adjusted difference = 2.9, CI95% = 1.2-4.6, p = .001). No change was observed in health behaviours. Sixty two percent of participants completed 6 or more of the 12 weekly remote individualized health coaching sessions. Nine (39%) low intensity and 12 (41%) high intensity participants completed the final follow-up.Personalized health coaching for youth with psychosis is feasible and may have sustained benefits. However, retention with this population for 12 weeks is challenging.
- Published
- 2022
29. Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction
- Author
-
Tarek K, Rajji, David C, Mamo, Jason, Holden, Eric, Granholm, and Benoit H, Mulsant
- Subjects
Ontario ,Social Skills ,Psychiatry and Mental health ,Cognition ,Treatment Outcome ,Cognitive Behavioral Therapy ,Schizophrenia ,Humans ,Middle Aged ,Biological Psychiatry ,Aged - Abstract
The objectives of this study are to test the efficacy of Cognitive-Behavioral Social Skills Training (CBSST) in enhancing social function in a sample of older patients with schizophrenia, and to assess whether baseline cognition moderates response to CBSST. To address these objectives, we conducted a randomized controlled trial of 63 participants, randomized 1:1 into CBSST or Treatment-As-Usual (TAU). The setting was a community-based geriatric mental health outpatient clinic in Toronto, Ontario, Canada. Data were collected at baseline, and week 18, 36 and 52, between June 2008 and May 2014. Participants were outpatients, aged 60 or older, with a diagnosis of schizophrenia or schizoaffective disorder and no evidence of dementia or other conditions associated with cognitive or functional impairment. The intervention was a weekly group CBSST for 36 weeks. Cognition, including executive function, was assessed at baseline. Modified total score on the Independent Living Skills Survey (ILSS) at 18, 36, and 52 weeks was the primary outcome measure. In a linear mixed model analysis, the ILSS trajectory was better in the CBSST group than the TAU group, with significantly better function at 36 (Cohen's d = 0.75) and 52 weeks (Cohen's d = 0.92). Baseline executive dysfunction moderated CBSST response, whereby participants with more severe executive dysfunction experienced the most improvement in ILSS. CBSST was efficacious in patients with late-life schizophrenia and prevented decline in social function over a one-year period. CBSST was most beneficial for patients with more severe executive dysfunction, i.e., those who needed skills training the most.
- Published
- 2022
30. Corrigendum to Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized. Am J Geriatr Psychiatry 2019;27(10):1138–1152. doi: 10.1016/j.jagp.2019.04.005
- Author
-
Pilar Cristancho, Emily Lenard, Eric J. Lenze, J. Philip Miller, Patrick J. Brown, Steven P. Roose, Carolina Montes-Garcia, Daniel M. Blumberger, Benoit H. Mulsant, Helen Lavretsky, Bruce L. Rollman, Charles F. Reynolds, and Jordan F. Karp
- Subjects
Psychiatry and Mental health ,Geriatrics and Gerontology - Published
- 2023
31. 98. Cellular Senescence in Late-Life Depression
- Author
-
Johanna Seitz-Holland, Benoit H. Mulsant, Charles F. Reynolds, Daniel M. Blumberger, Jordan F. Karp, Meryl A. Butters, Ana Paula Mendes-Silva, Erica L. Vieira, George Tseng, Eric J. Lenze, and Breno S. Diniz
- Subjects
Biological Psychiatry - Published
- 2023
32. 'What else can we do?'—Provider perspectives on treatment‐resistant depression in late life
- Author
-
Megan Hamm, Eric J. Lenze, Patrick J. Brown, Helen Lavretsky, Emily Lenard, Steven P. Roose, Jordan F. Karp, Alicia Dawdani, Benoit H. Mulsant, and Charles F. Reynolds
- Subjects
Psychiatry ,Referral ,Attitude of Health Personnel ,Depression ,business.industry ,Telehealth ,medicine.disease ,Mental health ,Integrated care ,Nursing ,medicine ,Humans ,Geriatrics and Gerontology ,Knowledge dissemination ,business ,Referral and Consultation ,Treatment-resistant depression ,Qualitative Research ,Depression (differential diagnoses) ,Aged ,Qualitative research - Abstract
BACKGROUND Treatment-resistant depression in late-life (TRLLD) is common. Perspectives of primary care providers (PCPs) and psychiatrists treating TRLLD could give insights into the challenges and potential solutions for managing this condition. METHODS To identify perspectives of providers who treat TRLLD, we conducted a qualitative descriptive study using semi-structured interviews with providers treating older adults with TRLLD in five locations across North America (i.e., Los Angeles, New York City, Pittsburgh, St. Louis, and Toronto). We conducted semi-structured interviews with 50 care providers (24 primary care providers [PCPs], 22 psychiatrists, and 4 depression care managers). Interviews elicited providers' perspectives on treatment options for TRLLD, including treatment within the primary care setting and referral to psychiatry, and sought suggestions for improvement. RESULTS We identified four themes. (1) Treating TRLLD takes an emotional toll on providers; (2) existing psychiatric services are inadequate to meet the needs of patients with TRLLD, mainly because of lack of access; (3) PCPs often attempt to treat TRLLD, even when they are not comfortable doing so; and (4) to better meet the needs of patients with TRLLD, providers recommend integrated care models involving PCPs, psychiatrists, and psychotherapists, potentially made more feasible by the growth of telehealth. CONCLUSIONS Findings from these qualitative interviews show the challenges in providing care for TRLLD. These findings can guide knowledge dissemination to psychiatrists, PCPs, policy-makers, and other stakeholders involved in the mental health system. They can also inform structural changes to clinical practice that may increase the implementation of the best treatment strategies across settings to improve long-term outcomes for TRLLD.
- Published
- 2021
33. Apps and gaps in bipolar disorder: A systematic review on electronic monitoring for episode prediction
- Author
-
Zafiris J. Daskalakis, M. Ishrat Husain, Abigail Ortiz, Benoit H. Mulsant, and Marta M. Maslej
- Subjects
Adult ,medicine.medical_specialty ,Bipolar Disorder ,Web of science ,business.industry ,MEDLINE ,PsycINFO ,medicine.disease ,Affect ,Psychiatry and Mental health ,Clinical Psychology ,Systematic review ,Mood ,medicine ,Humans ,Smartphone ,Bipolar disorder ,Electronics ,Intensive care medicine ,business ,Software - Abstract
Background Long-term clinical monitoring in bipolar disorder (BD) is an important therapeutic tool. The availability of smartphones and wearables has sparked the development of automated applications to remotely monitor patients. This systematic review focus on the current state of electronic (e-) monitoring for episode prediction in BD. Methods We systematically reviewed the literature on e-monitoring for episode prediction in adult BD patients. The systematic review was done according to the guidelines for reporting of systematic reviews and meta-analyses (PRISMA) and was registered in PROSPERO on April 29, 2020 (CRD42020155795). We conducted a search of Web of Science, MEDLINE, EMBASE, and PsycINFO (all 2000–2020) databases. We identified and extracted data from 17 published reports on 15 relevant studies. Results Studies were heterogeneous and most had substantial methodological and technical limitations. Models varied widely in their performance. Published metrics were too heterogeneous to lend themselves to a meta-analysis. Four studies reported sensitivity (range: 0.21 - 0.95); and two reported specificity for prediction of mood episodes (range: 0.36 - 0.99). Two studies reported accuracy (range: 0.64 - 0.88) and four reported area under the curve (AUC; range: 0.52-0.95). Overall, models were better in predicting manic or hypomanic episodes, but their performance depended on feature type. Limitations Our conclusions are tempered by the lack of appropriate information impeding our ability to synthesize the available evidence. Conclusions Given the clinical variability in BD, predicting mood episodes remains a challenging task. Emerging e-monitoring technology for episode prediction in BD requires more development before it can be adopted clinically.
- Published
- 2021
34. Enhancing Cognition in Older Persons with Depression or Anxiety with a Combination of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS): Results of a Pilot Randomized Clinical Trial
- Author
-
Heather Brooks, Daniel M. Blumberger, Lojine Kamel, Benoit H. Mulsant, Sanjeev Kumar, Jeanne Kloeckner, Hanadi Ajam Oughli, Subha Subramanian, Tarek K. Rajji, Gwen Morgan, and Eric J. Lenze
- Subjects
medicine.medical_specialty ,Health (social science) ,Mindfulness ,Social Psychology ,medicine.medical_treatment ,Experimental and Cognitive Psychology ,MBSR ,Late-life depression ,tDCS ,law.invention ,Mindfulness-based stress reduction ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Developmental and Educational Psychology ,medicine ,Late-life anxiety ,Cognitive decline ,Applied Psychology ,Original Paper ,030214 geriatrics ,Transcranial direct-current stimulation ,Cognition ,Subjective cognitive complaints ,Late life depression ,3. Good health ,Physical therapy ,Anxiety ,Cognitive function ,medicine.symptom ,Psychology ,030217 neurology & neurosurgery - Abstract
Objectives Individuals with subjective memory complaints and symptoms of depression and/or anxiety are at high risk for further cognitive decline, and possible progression to dementia. Low-burden interventions to help slow or prevent cognitive decline in this high-risk group are needed. The objective of this study is to assess the feasibility of combining Mindfulness-Based Stress Reduction (MBSR) with transcranial direct current stimulation (tDCS) to increase putative benefits of MBSR for cognitive function and everyday mindfulness in depressed or anxious older adults with subjective cognitive decline. Methods We conducted a two-site pilot double-blind randomized sham-controlled trial, combining active MBSR with either active or sham tDCS. The intervention included weekly in-class group sessions at the local university hospital and daily at-home practice. Anodal tDCS was applied for 30 min during MBSR meditative practice, both in-class and at-home. Results Twenty-six individuals with subjective cognitive complaints and symptoms of depression and/or anxiety were randomized to active (n = 12) or sham tDCS (n = 14). The combination of MBSR and tDCS was safe and well tolerated, though at-home adherence and in-class attendance were variable. While they were not statistically significant, the largest effect sizes for active vs. sham tDCS were for everyday mindfulness (d = 0.6) and social functioning (d = 0.9) (F(1,21) = 3.68, p = 0.07 and F(1,21) = 3.9, p = 0.06, respectively). Conclusions Our findings suggest that it is feasible and safe to combine tDCS with MBSR in older depressed and anxious adults, including during remote, at-home use. Furthermore, tDCS may enhance MBSR via transferring its meditative learning and practice into increases in everyday mindfulness. Future studies need to improve adherence to MBSR with tDCS. Trial Registration ClinicalTrials.gov (NCT03653351 and NCT03680664). Supplementary Information The online version contains supplementary material available at 10.1007/s12671-021-01764-9.
- Published
- 2021
35. Sex Modifies the Associations of APOEɛ4 with Neuropsychiatric Symptom Burden in Both At-Risk and Clinical Cohorts of Alzheimer's Disease
- Author
-
Andrew S, Dissanayake, Yu Bin, Tan, Christopher R, Bowie, Meryl A, Butters, Alastair J, Flint, Damien, Gallagher, Angela C, Golas, Nathan, Herrmann, Zahinoor, Ismail, James L, Kennedy, Sanjeev, Kumar, Krista L, Lanctot, Linda, Mah, Benoit H, Mulsant, Bruce G, Pollock, Tarek K, Rajji, Michael, Tau, Anika, Maraj, Nathan W, Churchill, Debby, Tsuang, Tom A, Schweizer, David G, Munoz, and Corinne E, Fischer
- Abstract
Recent work suggests that APOEɛ4/4 females with Alzheimer's disease (AD) are more susceptible to developing neuropsychiatric symptoms (NPS).To examine the interaction of sex and APOEɛ4 status on NPS burden using two independent cohorts: 1) patients at risk for AD with mild cognitive impairment and/or major depressive disorder (n = 252) and 2) patients with probable AD (n = 7,261).Regression models examined the interactive effects of sex and APOEɛ4 on the number of NPS experienced and NPS Severity. APOEɛ3/4 and APOEɛ4/4 were pooled in the at-risk cohort due to the sample size.In the at-risk cohort, there was a significant sex*APOEɛ4 interaction (p = 0.007) such that the association of APOEɛ4 with NPS was greater in females than in males (incident rate ratio (IRR) = 2.0). APOEɛ4/4 females had the most NPS (mean = 1.9) and the highest severity scores (mean = 3.5) of any subgroup. In the clinical cohort, APOEɛ4/4 females had significantly more NPS (IRR = 1.1, p = 0.001, mean = 3.1) and higher severity scores (b = 0.31, p = 0.015, mean = 3.7) than APOEɛ3/3 females (meanNPS = 2.9, meanSeverity = 3.3). No association was found in males.Our study suggests that sex modifies the association of APOEɛ4 on NPS burden. APOEɛ4/4 females may be particularly susceptible to increased NPS burden among individuals with AD and among individuals at risk for AD. Further investigation into the mechanisms behind these associations are needed.
- Published
- 2022
36. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap
- Author
-
Nicole Ledwos, Joshua D. Rosenblat, Daniel M. Blumberger, David J. Castle, Roger S. McIntyre, Benoit H. Mulsant, and M. Ishrat Husain
- Subjects
Death ,Psychiatry and Mental health ,Lysergic Acid Diethylamide ,Depressive Disorder, Major ,Serotonin Agents ,Banisteriopsis ,Hallucinogens ,Humans ,Pharmacology (medical) ,Antidepressive Agents ,Psilocybin - Abstract
There has been resurgence of interest in the therapeutic use of serotonergic ("classic") psychedelics in major depressive disorder (MDD) and end-of-life distress. This commentary offers a critical appraisal of current evidence for antidepressant effects of classic psychedelics from contemporary clinical trials and highlights pitfalls that should be addressed before clinical translation.A narrative review was conducted to identify clinical trials of serotonergic psychedelics for the treatment of MDD and end-of-life distress. Trials published between January 1990 and May 2022 were identified on PubMed using combinations of search terms.Psilocybin, lysergic acid diethylamide, and ayahuasca have clinical trials to evaluate antidepressant effects. Two studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression. Similar results were seen in lysergic acid diethylamide for end-of-life distress. Small randomized clinical trials (RCTs) of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator in MDD, with additional RCTs showing efficacy in end-of-life distress. Adverse events associated with psychedelics were reported as mild and transient. Small homogenous samples, expectancy bias, functional unblinding, and lack of consensus and standardization of psychotherapy are major limitations of all studies.Given the methodological limitations of published RCTs, the evidence supporting the efficacy and safety of serotonergic psychedelics for depression is currently of low level. Future research should assess the role of expectancy and psychedelic effects in moderating and mediating treatment response. Innovative trial designs are needed to overcome functional unblinding. For now, psychedelics should remain experimental interventions used within clinical trials.
- Published
- 2022
37. Brain-cognition relationships in late-life depression: a systematic review of magnetic resonance imaging studies
- Author
-
Tulip Marawi, Nicholas J. Ainsworth, Peter Zhukovsky, Neda Rashidi-Ranjbar, Tarek Rajji, Maria Carmela Tartaglia, Aristotle Voineskos, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Geriatrics and Gerontology - Published
- 2023
38. Decision trees for when to change pharmacotherapy in late-life depression: integration of pharmacogenetics, venlafaxine pharmacokinetics, and clinical predictors
- Author
-
Helena K. Kim, Xiaoyu Men, Daniel M. Blumberger, Jordan F. Karp, Eric Lenze, Daniel J. Müller, Laura B. Ramsey, Charles F. Reynolds, Zachary L. Taylor, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Geriatrics and Gerontology - Published
- 2023
39. Brain-cognition associations in late-life depression or mild cognitive impairment: A multivariate analysis of white and gray matter integrity
- Author
-
Tulip Marawi, Peter Zhukovsky, Neda Rashidi-Ranjbar, Corinne Fischer, Alastair Flint, Nathan Herrmann, Linda Mah, Bruce Pollock, Tarek Rajji, Maria Carmela Tartaglia, Aristotle Voineskos, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Geriatrics and Gerontology - Published
- 2023
40. Assessing the Longitudinal Relationship between Theta-Gamma Coupling and Working Memory Performance in Older Adults
- Author
-
Krista L. Lanctôt, Daniel M. Blumberger, Zafiris J. Daskalakis, Tarek K. Rajji, Michelle S. Goodman, Mina Mirjalili, Wei Wang, Alastair J. Flint, Reza Zomorrodi, Bruce G. Pollock, Sanjeev Kumar, Nathan Herrmann, Linda Mah, Heather Brooks, Aristotle N. Voineskos, Corinne E. Fischer, Christopher R. Bowie, and Benoit H. Mulsant
- Subjects
medicine.medical_specialty ,Cognitive Neuroscience ,Alpha (ethology) ,Event related synchronization ,Audiology ,Electroencephalography ,050105 experimental psychology ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Cognition ,0302 clinical medicine ,medicine ,Humans ,0501 psychology and cognitive sciences ,Cortical Synchronization ,skin and connective tissue diseases ,Aged ,Depressive Disorder, Major ,Cross frequency coupling ,medicine.diagnostic_test ,Working memory ,business.industry ,Event related desynchronization ,05 social sciences ,Middle Aged ,medicine.disease ,Memory, Short-Term ,Major depressive disorder ,Original Article ,sense organs ,Cognition Disorders ,business ,030217 neurology & neurosurgery - Abstract
Theta-gamma coupling (TGC) is a neurophysiologic mechanism that supports working memory (WM). TGC is associated with N-back performance, a WM task. Similar to TGC, theta and alpha event-related synchronization (ERS) and desynchronization (ERD) are also associated with WM. Few studies have examined the longitudinal relationship between WM performance and TGC, ERS, or ERD. This study aimed to determine if changes in WM performance are associated with changes in TGC (primary aim), as well as theta and alpha ERS or ERD over 6 to 12 weeks. Participants included 62 individuals aged 60 and older with no neuropsychiatric conditions or with remitted Major Depressive Disorder (MDD) and no cognitive disorders. TGC, ERS, and ERD were assessed using electroencephalography (EEG) during the N-back task (3-back condition). There was an association between changes in 3-back performance and changes in TGC, alpha ERD and ERS, and theta ERS in the control group. In contrast, there was only a significant association between changes in 3-back performance and changes in TGC in the subgroup with remitted MDD. Our results suggest that the relationship between WM performance and TGC is stable over time, while this is not the case for changes in theta and alpha ERS and ERD.
- Published
- 2021
41. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study
- Author
-
Anthony J. Rothschild, Aristotle N. Voineskos, Yiyuan Wu, Ellen M. Whyte, Cristina Pollari, Benoit H. Mulsant, George S. Alexopoulos, Patricia Marino, Samprit Banerjee, Barnett S. Meyers, and Alastair J. Flint
- Subjects
Adult ,Male ,Olanzapine ,medicine.medical_specialty ,Adolescent ,Psychotic depression ,Placebo ,law.invention ,Benzodiazepines ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Randomized controlled trial ,law ,Sertraline ,Internal medicine ,Post-hoc analysis ,medicine ,Humans ,Aged ,Aged, 80 and over ,030214 geriatrics ,Depression ,business.industry ,Middle Aged ,medicine.disease ,Psychiatry and Mental health ,Treatment Outcome ,Tolerability ,Drug Therapy, Combination ,Female ,Geriatrics and Gerontology ,medicine.symptom ,business ,Weight gain ,Antipsychotic Agents ,medicine.drug - Abstract
Objective To examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine. Methods Two hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures. Results Participants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18–59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures. Conclusion Older patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not.
- Published
- 2021
42. Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression: The FOUR-D Randomized Noninferiority Clinical Trial
- Author
-
Daniel M. Blumberger, Benoit H. Mulsant, Kevin E. Thorpe, Shawn M. McClintock, Gerasimos N. Konstantinou, Hyewon H. Lee, Sean M. Nestor, Yoshihiro Noda, Tarek K. Rajji, Alisson P. Trevizol, Fidel Vila-Rodriguez, Zafiris J. Daskalakis, and Jonathan Downar
- Subjects
Male ,Ontario ,Psychiatry and Mental health ,Depressive Disorder, Major ,Depressive Disorder, Treatment-Resistant ,Treatment Outcome ,Depression ,Humans ,Prefrontal Cortex ,Female ,Transcranial Magnetic Stimulation ,Aged - Abstract
ImportanceTreatment-resistant depression (TRD) is common in older adults. Bilateral repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex for 48 minutes has demonstrated efficacy in TRD. Theta burst stimulation (TBS), a newer form of rTMS, can also be delivered bilaterally using left intermittent TBS and right continuous TBS for only 4 minutes.ObjectiveTo establish the effectiveness and tolerability of TBS compared with standard rTMS in older adults with TRD.Design, Setting, and ParticipantsIn this randomized noninferiority trial with open treatment and blinded assessors, recruitment occurred between December 2016 and March 2020. The trial was conducted at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada and included outpatients 60 years and older with a diagnosis of depression, moderate severity, and nonresponse to 1 or more antidepressant trial of adequate dosage and duration or intolerance of 2 or more trials.InterventionsParticipants were randomized to receive a course of 4 to 6 weeks of either bilateral standard rTMS or TBS.Main Outcomes and MeasuresThe primary outcome measure was change in Montgomery-Åsberg Depression Rating Scale; secondary outcome measures included the 17-item Hamilton Rating Scale for Depression, Quick Inventory of Depressive Symptomatology (16-item) (self-report), and dropout rates. A noninferiority margin of 2.75 points was used for the primary outcome. All participants who attained the primary completion point of 4 weeks were analyzed.ResultsA total of 87 participants (mean [SD] age, 67.1 [6.7] years; 47 [54.0%] female) were randomized to standard bilateral rTMS and 85 (mean [SD] age, 66.3 [5.3] years; 45 [52.9%] female) to TBS, of whom 85 (98%) and 79 (93%) were assessed for the primary outcome, respectively, whereas tolerability was assessed in all randomized participants. In the rTMS group, 4 (4.6%) were American Indian, reported other, or preferred not to answer; 5 (5.8%) were Asian; and 78 (89.7%) were White. In the TBS group, 6 (7.1%) were Asian, 2 (2.4%) were Black or reported other, and 77 (90.3%) were White. Mean (SD) Montgomery-Åsberg Depression Rating Scale total scores improved from 25.6 (4.0) to 17.3 (8.9) for rTMS and 25.7 (4.7) to 15.8 (9.1) for TBS (adjusted difference, 1.55; lower 95% CI −0.67), establishing noninferiority for TBS. The all-cause dropout rates were relatively similar between groups (rTMS: 2 of 87 [2.3%]; TBS: 6 of 85 [7.1%]; P = .14; χ2 = 2.2).Conclusions and RelevanceIn older adults with TRD, bilateral TBS compared with standard bilateral rTMS achieved noninferior reduction in depression symptoms. Both treatments had low and similar dropout rates. Using TBS rather than rTMS could increase access to treatment several-fold for older adults with TRD.Trial RegistrationClinicalTrials.gov Identifier: NCT02998580
- Published
- 2022
43. Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-Analysis
- Author
-
Argyrios, Perivolaris, Nicholas J, Ainsworth, George S, Alexopoulos, Kathleen S, Bingham, Alastair J, Flint, Patricia, Marino, Nicholas H, Neufeld, Anthony J, Rothschild, Aristotle N, Voineskos, Ellen M, Whyte, and Benoit H, Mulsant
- Subjects
Depressive Disorder, Major ,Humans ,Placebo Effect ,Antidepressive Agents ,Randomized Controlled Trials as Topic - Abstract
In the 1980s, the response rate of major depressive disorder with psychotic features (MDD-Psy) to placebo pills was reported to be close to 0%. To our knowledge, this placebo response rate has not been systematically reassessed. We undertook a systematic review of randomized controlled trials (RCTs) that have used a placebo or sham control group for MDD-Psy.We searched MEDLINE and identified 9 relevant publications reporting on 10 studies comparing a placebo or sham interventions versus an active intervention. We extracted reported rates of response or of dropout for all causes associated with placebo versus active intervention(s) and aggregated response and dropout rates across trials.Two sham-controlled electroconvulsive therapy (ECT) trials did not provide response rates. In the 3 pharmacotherapy studies published in the 1980s, 0 of 12 participants (0%) responded to placebo versus 13 of 38 (34.2%) responding to the active interventions. In contrast, 5 RCTs published in the 2000s, 114 of 339 participants (33.6%) randomized to placebo responded versus 149 of 373 participants (39.9%) randomized to active interventions; dropout rates were 71/236 (30.1%) for placebo versus 84/282 (29.8%) for the active interventions.As expected, response rates to placebo pills in RCTs for MDD-Psy increased markedly from the 1980s to the 2000s. Methodological issues in the design and conduct of more recent RCTs may have contributed to the high placebo response. However, one needs to consider this placebo response rate when interpreting the result of recent trials of MDD-Psy, which typically have not included a "pure" placebo condition.
- Published
- 2022
44. Late-Life Depression is Associated With Increased Levels of GDF-15, a Pro-Aging Mitokine
- Author
-
Emma Mastrobattista, Eric J. Lenze, Charles F. Reynolds, Benoit H. Mulsant, Julie Wetherell, Gregory F. Wu, Daniel M. Blumberger, Jordan F. Karp, Meryl A. Butters, Ana Paula Mendes-Silva, Erica L. Vieira, George Tseng, and Breno S. Diniz
- Subjects
Male ,Psychiatry and Mental health ,Depressive Disorder, Major ,Aging ,Growth Differentiation Factor 15 ,Depression ,Humans ,Female ,Comorbidity ,Geriatrics and Gerontology ,Biomarkers ,Aged - Abstract
In older adults, major depressive disorder (MDD) is associated with accelerated physiological and cognitive aging, generating interest in uncovering biological pathways that may be targetable by interventions. Growth differentiation factor-15 (GDF-15) plays a significant role in biological aging via multiple biological pathways relevant to age and age-related diseases. Elevated levels of GDF-15 correlate with increasing chronological age, decreased telomerase activity, and increased mortality risk in older adults. We sought to evaluate the circulating levels of GDF-15 in older adults with MDD and its association with depression severity, physical comorbidity burden, age of onset of first depressive episode, and cognitive performance.This study assayed circulating levels of GDF-15 in 393 older adults (mean ± SD age 70 ± 6.6 years, male:female ratio 1:1.54), 308 with MDD and 85 non-depressed comparison individuals.After adjusting for confounding variables, depressed older adults had significantly higher GDF-15 serum levels (640.1 ± 501.5 ng/mL) than comparison individuals (431.90 ± 223.35 ng/mL) (t=3.75, d.f.= 391, p=0.0002). Among depressed individuals, those with high GDF-15 had higher levels of comorbid physical illness, lower executive cognitive functioning, and higher likelihood of having late-onset depression.Our results suggest that depression in late life is associated with GDF-15, a marker of amplified age-related biological changes. GDF-15 is a novel and potentially targetable biological pathway between depression and accelerated aging, including cognitive aging.
- Published
- 2022
45. Corrigendum to 'Cognitive-behavioral social skills training for patients with late-life schizophrenia and the moderating effect of executive dysfunction' [Schizophr. Res. 239 (2022) 160–167]
- Author
-
Tarek K. Rajji, David C. Mamo, Jason Holden, Eric Granholm, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Biological Psychiatry - Published
- 2022
46. Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia
- Author
-
Keisuke Kusudo, Ryo Ochi, Shinichiro Nakajima, Takefumi Suzuki, David Mamo, Fernando Caravaggio, Wanna Mar, Philip Gerretsen, Masaru Mimura, Bruce G. Pollock, Benoit H. Mulsant, Ariel Graff-Guerrero, Tarek K. Rajji, and Hiroyuki Uchida
- Subjects
Psychiatry and Mental health ,Biological Psychiatry - Published
- 2022
47. 26. Adjunctive Simvastatin for Treatment-Resistant Depression: A Randomized Clinical Trial
- Author
-
Muhammad Ishrat Husain, Imran Chaudhry, Ameer Bukhsh Khoso, Tayyeba Kiran, Nawaz Khan, Farooq Ahmad, John Hodsoll, Muhammad Omair Husain, Haider Ali Naqvi, Asad Tamizuddin Nizami, Nasim Chaudhry, Hazrat Ali Khan, Fareed Minhas, Jeffrey H. Meyer, Moin Ansar, Benoit H. Mulsant, Nusrat Husain, and Allan H. Young
- Subjects
Biological Psychiatry - Published
- 2023
48. 117. Brain-Cognition Associations in Late-Life Depression and Mild Cognitive Impairment: A Multivariate Analysis of White and Gray Matter Integrity
- Author
-
Tulip Marawi, Peter Zhukovsky, Neda Rashidi-Ranjbar, Christopher Bowie, Corinne E. Fischer, Alastair J. Flint, Nathan Herrmann, Linda Mah, Bruce G. Pollock, Tarek K. Rajji, Maria Carmela Tartaglia, Aristotle N. Voineskos, and Benoit H. Mulsant
- Subjects
Biological Psychiatry - Published
- 2023
49. An update on antidepressant pharmacotherapy in late-life depression
- Author
-
Benoit H. Mulsant, Ram Brender, and Daniel M. Blumberger
- Subjects
medicine.medical_specialty ,03 medical and health sciences ,Cognition ,0302 clinical medicine ,Pharmacotherapy ,medicine ,Humans ,Pharmacology (medical) ,Adverse effect ,Intensive care medicine ,Depression (differential diagnoses) ,Aged ,Pharmacology ,Depression ,business.industry ,General Medicine ,Middle Aged ,Late life depression ,medicine.disease ,Antidepressive Agents ,Pharmacogenetics ,030220 oncology & carcinogenesis ,Major depressive disorder ,Antidepressant ,business ,030217 neurology & neurosurgery - Abstract
Introduction: Clinically important depressive symptoms that occur in adults over age 60 are often termed late-life depression (LLD). LLD poses challenges for treating clinicians in both detection and treatment. Antidepressants are the most common first-line treatment approach. Older adults are at an increased risk of adverse effects because of polypharmacy.Areas covered: This article summarizes the challenges and approaches when using pharmacotherapy in LLD with a focus on newer data that have become available during the last five years. While no new antidepressants have become available during this period, a review of the literature summarizes advances in the knowledge of the adverse effects associated with various antidepressants and on the potential contribution of pharmacogenetic tools when prescribing antidepressants to older patients.Expert opinion: During the past 5 years, most of the literature relevant to the pharmacotherapy of MDD in older patients has focused on adverse effects. In particular, the effects of antidepressants on cognition and bone are emerging as important areas for clinical attention and further investigation. There is also an emerging literature on the potential role of pharmacogenetic testing in patients with MDD, though recommendations for use in older adults await larger studies that demonstrate its efficacy and cost-effectiveness.
- Published
- 2021
50. From challenge to opportunity: COVID-19 and the evolution of virtual mental health care
- Author
-
Nicholas J. Ainsworth, M. Ishrat Husain, and Benoit H. Mulsant
- Subjects
Psychiatry and Mental health ,Mental Health ,SARS-CoV-2 ,COVID-19 ,Humans ,Pandemics ,Telemedicine ,Applied Psychology - Abstract
The transition to virtual care (telehealth) during the COVID-19 pandemic has led to both challenges and opportunities in delivering effective mental health care that meets the needs of patients and families. The negative mental and physical health effects of isolation and loneliness associated with the pandemic present a challenge for community mental and behavioral health care. However, the advantages that virtual care provides for the delivery of mental health services, particularly the potential for improved access, also benefit both providers and patients. Ongoing barriers to wider adoption and utilization of virtual mental health care need to be addressed. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.